Supplementary materials
. FLT3-ITD primary AML cells which are procured from BRCF Biospecimen Repository Core Facility of Kansas University Medical Center, Kansas City, KS and used under ethical permit of BRCF Biospecimen Repository Core Facility of Kansas University Medical Center.
Cell lysis, western blotting, cell viability and apoptosis assays: Cells were lysed in 1% Triton-X 100 lysis buffer supplemented with protease and phosphatase inhibitors. The western blotting procedure was described previously 4 . Cell viability was measured using PrestoBlue (Thermo Fischer) following the protocol provided by the manufacturer. Apoptosis was measured by Annexin V and 7-amino actinomycin D (7-AAD) apoptosis kit (BD Biosciences, Franklin Lakes, NJ).
Peptide-based kinase profiling: PamGene technology for kinase profiling (PamGene, Hertogenbosch, the Netherlands) was used to measure upregulated kinase activities. MOLM-13 cells were serum-starved for 16h before lysis. Tyrosine kinase profiling was performed using standard protocols provided by the manufacturer.
Animal experiment: Ten female NOD scid gamma (NSG) mice each weighing approximately 20 g, (housed by the Laboratory Animal Facilities at Medicon Village, Lund University) were injected subcutaneously with 4 million cells. Mice were then divided into two groups that were either treated with AZD3463 or vehicle. One week after injection of cells, mice were treated six days weekly by intraperitoneal (IP) injection of 15 mg/kg AZD3463 or vehicle for additional seven days. Tumor volume was measured and all mice were sacrificed when one of the tumors reached around 1000 mm 3 . The animal experiment was performed under an ethical permit from the Swedish Animal Welfare Authority.
Statistical analysis: All statistical analysis was performed using GraphPad Prism 5.0. For multiple comparisons One-way ANOVA was used. Otherwise, student's t-test was used to compare in between two groups.
Supplementary figures:
Figure S1: Tyrosine kinase profiling in MOLM-13 cells. 
